tucatinib,trastuzumab deruxtecan,trastuzumab
roche,seagen,daiichi sankyo,astrazeneca
['herceptin', 'tuca ', 'enhertu', 'breast']
 prefer traz tuca second line - lot of the tuca toxicity in breast is due to concurrent xeloda . tuca+ herceptin should be much easier to tolerate - ild risk frm enhertu
- not sure whether tuca+ herceptin will do much after enhertu progression ( not data for the reverse either)
Doing my part to help onc patients. + fintwit